Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)
Status:
Completed
Trial end date:
2021-03-19
Target enrollment:
Participant gender:
Summary
This is a multicenter, worldwide, open-label study of MK-8353 in combination with selumetinib
in participants with histologically or cytologically confirmed diagnosis of advanced solid
tumor. This study will evaluate the safety, tolerability, and preliminary efficacy of MK-8353
in combination with selumetinib.